March 2026 Research Update

This month adds clearer evidence that some detailed brain imaging measures may help separate children with juvenile metachromatic leukodystrophy (MLD) into different long-term paths, even when more general MRI scores do not. In a group of children receiving hematopoietic stem cell transplantation (HSCT), certain baseline signs of more widespread or more severe white matter injury were linked to a more severe course over years of follow-up. This supports the idea that the most useful imaging information may come from specific quantitative measures rather than relying only on overall MRI severity impressions. [1]

At the time of HSCT, children who later had a severely progressive course tended to start out with a higher demyelination load (more loss of myelin on imaging), higher diffusion values in a key motor pathway region, and lower MR spectroscopy ratios that reflect reduced brain cell health. By contrast, a baseline MRI severity score and baseline brain volumes were not reported to predict which trajectory a child would follow. The study also noted that some baseline spectroscopy measures could retrospectively separate children who initially looked mildly affected in motor function into distinct outcome groups. [1]

Over a median 5-year follow-up, imaging differences between outcome groups became easier to see using measures like lesion burden and brain volume changes, and these differences were largest in those with unfavorable trajectories. Diffusion and spectroscopy measures also changed over time, but they separated groups less consistently than the more visible changes in lesions and volumes. Taken together, these results point to a pattern where certain detailed baseline measures may help forecast risk, while longer-term imaging changes tend to mirror how the disease course unfolds. [1]

For families, this research mainly matters as an early step toward better prediction of how juvenile MLD might progress after HSCT, using information already collected in specialized MRI exams. It does not establish a single scan result that can predict an individual child's future, but it helps clarify which kinds of MRI measurements looked most informative in this small group. What remains uncertain is how well these markers work in broader, more diverse groups and whether they would perform similarly outside of this HSCT setting. For now, this is best understood as research that may matter more in the future if confirmed. [1]

This month also highlights that MLD-like disease can sometimes appear even when a key enzyme test is normal, which can complicate diagnosis. A single reported case showed that elevated urine sulfatides (a marker of sulfatide buildup) alongside typical MRI and nerve findings can still point toward an MLD pathway problem. The main change in understanding is a reminder that genetic causes outside the usual ARSA enzyme deficiency may need to be considered when the clinical picture fits but initial enzyme testing does not. [2]

In this child with juvenile-onset symptoms and a family history, urinary sulfatides were elevated but arylsulfatase A activity was reported as normal. Whole-exome sequencing found a homozygous PSAP variant, raising the possibility of saposin B deficiency, an atypical cause of an MLD-like condition. The report emphasized combining biochemical testing, brain imaging, and genetic testing when results do not line up, while noting that the variant was classified as uncertain and needs further validation. [2]

For patients and caregivers, this case mainly adds context for why a diagnostic workup can sometimes include more than one kind of test, especially when symptoms and imaging suggest MLD but an enzyme test does not. It helps clarify that there are rarer genetic routes to similar disease biology, which could explain confusing or mixed test results. Because this is a single case with an uncertain genetic variant, it does not tell how often this happens or how it affects outcomes, so it is best seen as a research and awareness signal rather than something that changes care by itself. [2]